Last reviewed · How we verify
Placebo and IVIG
IVIG (intravenous immunoglobulin) provides passive immunization by supplying pooled antibodies from healthy donors to modulate immune function, while placebo serves as the control comparator.
IVIG (intravenous immunoglobulin) provides passive immunization by supplying pooled antibodies from healthy donors to modulate immune function, while placebo serves as the control comparator. Used for Indication under investigation in phase 3 trial (specific indication not provided).
At a glance
| Generic name | Placebo and IVIG |
|---|---|
| Sponsor | The Hospital for Sick Children |
| Drug class | Immunoglobulin replacement therapy / Immunomodulator |
| Target | Multiple (Fc receptors, complement system, pathogenic antibodies) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
IVIG contains polyspecific immunoglobulins that can neutralize pathogens, block pathogenic antibodies, and modulate inflammatory immune responses through multiple mechanisms including Fc receptor engagement and complement inhibition. In this phase 3 trial context, IVIG is being evaluated against placebo to determine its therapeutic efficacy in a specific indication, likely an autoimmune or immunodeficiency condition.
Approved indications
- Indication under investigation in phase 3 trial (specific indication not provided)
Common side effects
- Headache
- Fever
- Chills
- Infusion reactions
- Thromboembolism
- Aseptic meningitis
Key clinical trials
- A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (PHASE3)
- A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy (PHASE3)
- Evaluating Efgartigimod in Patients With Guillain-Barré Syndrome (PHASE2)
- A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP (PHASE3)
- Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2 (PHASE2)
- Add-on Intravenous Immunoglobulins in Early Myositis (PHASE2, PHASE3)
- RECOVER-AUTONOMIC Platform Protocol (PHASE2)
- Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED). (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo and IVIG CI brief — competitive landscape report
- Placebo and IVIG updates RSS · CI watch RSS
- The Hospital for Sick Children portfolio CI